Opelconazole has the potential to be useful in a variety of conditions where Aspergillus has been implicated, including invasive pulmonary aspergillosis, aspergilloma, chronic necrotizing pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, and severe asthma with fungal sensitization. Opelconazole is initially being investigated for the acute treatment of invasive pulmonary aspergillosis in patients who are not responding to standard-of-care antifungal treatment, with the potential to be used in additional acute and chronic Aspergillus-associated conditions, as both a treatment and prophylaxis. Opelconazole has received several FDA designations that may facilitate its expedited development and/or review, including an orphan drug designation, Fast Track designation, and qualified infectious disease product (QIDP) designation. It has also been granted orphan drug designation in the European Union.
Preclinical
Phase 1
Phase 2
Phase 3
Treatment of Invasive Pulmonary Aspergillosis
Preclinical
Phase 1
Phase 2
Phase 3
Prophylaxis of Pulmonary Aspergillosis
Preclinical
Phase 1
Phase 2
Phase 3
Chronic Pulmonary Disease
(e.g. ABPA, SAFS, CPA)
Preclinical
Phase 1
Phase 2
Phase 3
Dry Powder Inhaler
Preclinical
Phase 1
Phase 2
Phase 3
Aspergillus is implicated in a number of acute and chronic conditions.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
CookieLawInfoConsent | 1 year | CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie. |
elementor | never | The website's WordPress theme uses this cookie. It allows the website owner to implement or change the website's content in real-time. |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
_ga | 1 year 1 month 4 days | Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors. |
_ga_* | 1 year 1 month 4 days | Google Analytics sets this cookie to store and count page views. |